ミカルディス錠２０ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00966 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 47 |
| 日本商品名（例） | テラムロ配合錠ＡＰ「サワイ」, テラムロ配合錠ＡＰ「トーワ」, テラムロ配合錠ＡＰ「ニプロ」 |
承認適応症（KEGG）
高血圧症
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | cerebral infarction | 99% | DL |
| 2 | obsolete susceptibility to ischemic stroke | 99% | DL |
| 3 | cerebrovascular disorder | 99% | DL |
| 4 | stroke disorder | 99% | DL |
| 5 | hypertensive disorder | 99% | DL |
| 6 | Prinzmetal angina | 99% | DL |
| 7 | brain stem infarction | 99% | DL |
| 8 | ABri amyloidosis | 99% | DL |
| 9 | cerebral artery occlusion | 99% | DL |
| 10 | pulmonary hypertension owing to lung disease and/or hypoxia | 99% | DL |
| 11 | pulmonary hypertension with unclear multifactorial mechanism | 99% | DL |
| 12 | malignant hypertensive renal disease | 99% | DL |
| 13 | malignant renovascular hypertension | 99% | DL |
| 14 | intracerebral hemorrhage | 99% | DL |
| 15 | Braddock syndrome | 99% | DL |
| 16 | cerebral arterial disease | 99% | DL |
| 17 | MRI defined brain infarct | 99% | DL |
| 18 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 99% | DL |
| 19 | brain small vessel disease 1 with or without ocular anomalies | 99% | DL |
| 20 | chronic pulmonary heart disease | 99% | DL |
| 21 | diabetic nephropathy | 99% | DL |
| 22 | spinal cord ischemia | 99% | DL |
| 23 | myocardial infarction | 99% | DL |
| 24 | posteroinferior myocardial infarction | 99% | DL |
| 25 | posterolateral myocardial infarction | 99% | DL |
| 26 | septal myocardial infarction | 99% | DL |
| 27 | cholesterol embolism | 99% | DL |
| 28 | sagittal sinus thrombosis | 98% | DL |
| 29 | homozygous familial hypercholesterolemia | 98% | DL |
| 30 | hypoalphalipoproteinemia | 98% | DL |
| 31 | chronic renal failure syndrome | 98% | DL |
| 32 | cardiac tamponade | 98% | DL |
| 33 | coronary thrombosis | 98% | DL |
| 34 | congenital coronary artery anomaly | 96% | DL |
| 35 | transient ischemic attack (disease) | 96% | DL |
| 36 | thrombophilia, familial, due to decreased release of tissue plasminogen activator | 95% | DL |
| 37 | angiokeratoma | 94% | DL |
| 38 | coronary stenosis | 94% | DL |
| 39 | atrial fibrillation (disease) | 94% | DL |
| 40 | obsolete familial combined hyperlipidemia | 93% | DL |
| 41 | sick sinus syndrome 2, autosomal dominant | 93% | DL |
| 42 | ABeta amyloidosis | 93% | DL |
| 43 | chronic kidney disease | 93% | DL |
| 44 | acute coronary syndrome | 93% | DL |
| 45 | sarcoglycanopathy | 91% | DL |
| 46 | end stage renal failure | 91% | DL |
| 47 | hypertension | 16% | DL |
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。